Related Experiment Video
Updated: Jun 18, 2026
Direct Bioprinting of 3D Multicellular Breast Spheroids onto Endothelial Networks
Published on: November 2, 2020
3D Bioprinting for Tumor Microenvironment Reconstruction: Advances, Challenges, and Future Perspectives
Ling-Jun Yao1, Pei-Lin Xie1, Ting-Xuan Huang2
1School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
Abstract:
Cancer remains a major global health burden, and the disconnect between preclinical models and clinical outcomes continues to hinder progress in oncology. Conventional two-dimensional (2D) cell cultures fail to recapitulate the in vivo tumor microenvironment (TME) and consequently show poor predictive power for drug responses. Animal models provide systemic insights but are constrained by interspecies differences, limited throughput, and high costs. Advanced three-dimensional (3D) in vitro platforms, such as spheroids, organoids, and organ-on-chip systems, have improved physiological relevance; however, they often lack the spatial control, reproducibility, and integrative capacity needed to capture the full complexity of the TME. This review posits that the unique value of 3D bioprinting in cancer research lies in its ability to reproducibly integrate the multicomponent complexity of the TME within a controllable spatial framework, a capability that no existing 3D model can provide simultaneously. We outline the technical foundation for TME reconstruction by 3D bioprinting, which encompasses bioink design, printing strategies, and the construction of complex tumor models. We subsequently summarize its applications in tumor biology, drug screening, personalized therapy and preclinical evaluation, and discuss translational challenges, interdisciplinary integration and future research directions. This review is intended to advance both basic cancer research and precision oncology.
Insights
Three-dimensional (3D) bioprinting offers a novel solution for cancer research by enabling the creation of complex tumor models that accurately mimic the tumor microenvironment (TME). This technology promises to improve preclinical drug screening and advance precision oncology.
Area of Science:
- Biomedical Engineering
- Cancer Research
- Oncology
Background:
- Current cancer research models, including 2D cultures and animal models, have limitations in replicating the in vivo tumor microenvironment (TME).
- Existing 3D in vitro platforms (spheroids, organoids, organ-on-chip) improve physiological relevance but often lack spatial control and reproducibility.
- A significant gap exists between preclinical findings and clinical outcomes in oncology due to inadequate model systems.
Purpose of the Study:
- To highlight the potential of 3D bioprinting in cancer research.
- To discuss how 3D bioprinting can overcome limitations of existing models for TME reconstruction.
- To explore applications and future directions of 3D bioprinting in oncology.
Main Methods:
- Review of technical foundations for TME reconstruction using 3D bioprinting.
- Discussion of bioink design, printing strategies, and complex tumor model construction.
- Summarization of applications in tumor biology, drug screening, and personalized therapy.
Main Results:
- 3D bioprinting enables reproducible integration of TME complexity within a controllable spatial framework.
- It offers a superior approach to existing 3D models for capturing TME intricacies.
- The technology facilitates advanced applications in cancer research and drug development.
Conclusions:
- 3D bioprinting is a transformative technology for cancer research, offering unprecedented control over TME reconstruction.
- It holds significant promise for improving drug screening accuracy, developing personalized therapies, and enhancing preclinical evaluations.
- Further interdisciplinary integration and research are crucial for realizing the full potential of 3D bioprinting in precision oncology.
